Search - tctmd.com

Displaying 81 - 100 of 351

Sort: Relevancy | Date

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Todd Neale

September 03, 2019

News Conference News ESC 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

Shelley Wood

September 01, 2019

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

Caitlin E. Cox

June 13, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

News Conference News ACC 2019

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Yael L. Maxwell

March 25, 2019

News Conference News ACC 2019

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

Yael L. Maxwell

March 18, 2019

News Daily News

African-American ACS Patients Less Often Treated With Prasugrel After PCI

Yael L. Maxwell

January 24, 2019

News Daily News

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

Todd Neale

January 14, 2019

News Daily News

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

L.A. McKeown

January 08, 2019

News Daily News

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

Caitlin E. Cox

November 28, 2018

News Daily News

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

L.A. McKeown

October 12, 2018

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

Shelley Wood

August 28, 2018

News Daily News

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Michael O'Riordan

July 31, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Daily News

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Michael O'Riordan

May 21, 2018

News Daily News

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Michael O'Riordan

May 01, 2018

Advertisement

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

New Clarity on Patients at High Risk for Bleeding After PCI

First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results

Dropping Aspirin: Two Trials Explore P2Y12 Monotherapy After Short-term DAPT Post-PCI

African-American ACS Patients Less Often Treated With Prasugrel After PCI

Crushing It: Cangrelor and Ticagrelor Can Be Used Together Safely in STEMI, Small Study Hints

Tailoring Antiplatelet Therapy to Bleeding Risk Post-PCI Improves Outcomes and Cuts Costs, Model Suggests

Metoclopramide May Mute Morphine’s Hampering of Ticagrelor Efficacy

Gender Gap May Be Narrowing in ACS Patients, With Mortality Advantage for Elderly Women

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

New Consensus Statement: NOAC and Clopidogrel for Most A-fib Patients Treated With PCI

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Women Underrepresented in Pivotal Studies Leading to FDA Drug Approval

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content